Gastrointestinal Cancer News

Labetuzumab govitecan monotherapy appeared safe and demonstrated activity in heavily pretreated patients with metastatic colorectal cancer, according to phase 1/phase 2 study results published in Journal of Clinical Oncology.

Interventions, such as the implementation of patient navigators and provider reminders, may improve follow-up colonoscopy rates of asymptomatic adults with positive fecal blood test results, according to data published in Annals of Internal Medicine.

Click here to read the Cover Story, “Obesity, hepatitis C epidemics drive ‘alarming’ increase in liver cancer incidence, mortality.”

A SEER analysis published this summer revealed staggering statistics about liver cancer in the United States.

H. Richard Alexander, MD, FACS, has been named chief surgical officer at Rutgers Cancer Institute.

Ben Z. Stanger, MD, PhD, associate professor of gastroenterology at Perelman School of Medicine at University of Pennsylvania, has been named director of the Penn Pancreatic Cancer Research Center.

Researchers identified young age, low baseline cancer antigen 19-9 and use of gemcitabine as a radiosensitizer as clinical factors associated with a major pathologic response following preoperative therapy for pancreatic ductal adenocarcinoma, according to results of a retrospective review.

The manufacturer of the Gore Viabil short wire biliary endoprosthesis, a fully covered, self-expanding metal biliary stent, announced it has launched an anti-migration assurance program that will replace devices that migrate within a year of implantation.

Patients with a higher number of DNA alterations detected by a liquid biopsy appeared more likely to respond to immune checkpoint inhibitors, according to retrospective study results published in Clinical Cancer Research.

Primary liver cancer incidence increased by 75% between 1990 and 2015, and the disease remains one of the leading causes of cancer death in the world, according to a report from the Global Burden of Diseases Study 2015.